ENT Service, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Neurosurgery Service and Gamma Knife Center, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
J Laryngol Otol. 2021 Feb;135(2):96-103. doi: 10.1017/S0022215121000323. Epub 2021 Feb 11.
This study aimed to provide a systematic review on survival outcome based on Pittsburgh T-staging for patients with primary external auditory canal squamous cell carcinoma.
This study was a systematic review in compliance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines performed until January 2018; pertinent studies were screened. Quality of evidence was assessed using the grading of recommendation, assessment, development and evaluation working group system.
Eight articles were chosen that reported on 437 patients with external auditory carcinoma. The 5-year overall survival rate was 53.0 per cent. The pooled proportion of survivors at 5 years for T1 tumours was 88.4 per cent and for T2 tumours was 88.6 per cent. For the combined population of T1 and T2 cancer patients, it was 84.5 per cent. For T3 and T4 tumours, it was 53.3 per cent and 26.8 per cent, respectively, whereas for T3 and T4 tumours combined, it was 40.4 per cent. Individual analysis of 61 patients with presence of cervical nodes showed a poor survival rate.
From this review, there was not any significant difference found in the survival outcome between T1 and T2 tumours. A practical classification incorporating nodal status that accurately stratifies patients was proposed.
本研究旨在对原发性外耳道鳞状细胞癌患者的匹兹堡 T 分期生存结果进行系统评价。
本研究为 2018 年 1 月前完成的符合系统评价和荟萃分析报告的首选项目的系统评价;筛选了相关研究。使用推荐分级评估、制定与评价工作组系统评估证据质量。
选择了 8 篇报道了 437 例外耳道癌患者的文章。5 年总生存率为 53.0%。T1 肿瘤 5 年生存率的合并比例为 88.4%,T2 肿瘤为 88.6%。T1 和 T2 癌症患者的合并比例为 84.5%。T3 和 T4 肿瘤的生存率分别为 53.3%和 26.8%,而 T3 和 T4 肿瘤合并的生存率为 40.4%。61 例颈部淋巴结阳性患者的个体分析显示生存率较差。
本研究中,T1 和 T2 肿瘤的生存结果无显著差异。提出了一种实用的分类方法,该方法纳入了淋巴结状态,可以准确分层患者。